-
Walvax Biotechnology Announces Positive Results for RQ3013 mRNA Vaccine
•
China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has announced the safety, immunogenicity, and protective efficacy results of a Phase IIIb clinical study for its RQ3013, a bivalent mRNA vaccine based on the S protein chimera of Alpha/Beta SARS-CoV-2 variants. The vaccine was co-developed by Shanghai Llanque Biomedical Co., Ltd and…
-
AIM Vaccine Initiates Phase I Clinical Study for MCV4 Meningococcal Vaccine in China
•
China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced the initiation of a single-center, open Phase I clinical study for its ACYW135 meningococcal polysaccharide conjugate vaccine, MCV4. The study is expected to enroll 120 subjects, marking a significant step in the development of this vaccine. Market Context and CompetitionCurrently, commercially…
-
Bochuang Biotechnology Secures Angel Funding for High-Purity Collagen and Innovative Medical Product Development
•
Jiangsu Bochuang Biotechnology Co., Ltd reportedly secured an undisclosed amount of funding in an angel financing round led exclusively by Dalton Venture. The proceeds will be utilized for the extraction of high-purity active collagen, the in-depth development of oral bone tissue-guided membrane adhesive and artificial cornea, and the establishment of…
-
NMPA Accepts Market Filing for Guangdong Zhongsheng’s COVID-19 Drug RAY1216
•
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced that the market filing for its drug candidate RAY1216, a 3CL protease (3CLpro) inhibitor, has been accepted for review by the National Medical Products Administration (NMPA). This marks a significant step towards the potential commercialization of the drug for COVID-19…
-
Mabwell Bioscience’s 9MW3811 Gains NMPA Approval for Clinical Trials in China
•
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its 9MW3811, an in-house developed IL-11 monoclonal antibody (mAb). The drug is intended for the treatment of various advanced malignant tumors and fibrotic diseases. It…
-
Everest Medicines’ Xerava Receives NMPA Approval for Complicated Intra-Abdominal Infections
•
China-based Everest Medicines Limited (HKG: 1952) has announced that it has received market approval from the National Medical Products Administration (NMPA) for its antibiotic Xerava (eravacycline). The approval is for the treatment of complicated intra-abdominal infections (cIAI) in adult patients in China, with plans to commercialize the product during the…
-
Terumo Blood and Cell Technologies Partners with EurekaBio to Establish Cell Therapy Lab
•
US-based Terumo Blood and Cell Technologies has entered into a partnership with Shenzhen-headquartered EurekaBio Technology to jointly establish a cell therapy process development platform laboratory. The collaboration aims to advance innovations in cell therapy, although no financial details were disclosed. About Terumo Blood and Cell TechnologiesTerumo Blood and Cell Technologies…
-
Beijing Initiates Volume-Based Procurement for Ophthalmology and Orthopedics Medical Consumables
•
The Beijing Municipal Medical Insurance Bureau has released a notification regarding the volume-based procurement (VBP) of ophthalmology and orthopedics medical consumables. The data filing process for this initiative began at 14:00 on March 17 and will continue until 17:00 on March 31. Ophthalmology Consumables IncludedThe notification specifies that the ophthalmology…
